Use of markers including filamin A in the diagnosis and treatment of prostate cancer

A method of treating prostate cancer in a subject, comprising:

• (i) obtaining diagnostic information as to the protein level of filamin A in a serum sample or a plasma sample from the subject, wherein the subject has elevated PSA and is symptomatic of prostate cancer, and (ii) administering a therapeutically effective amount of an anti-cancer therapy to the subject if the protein level of filamin A in the sample is increased relative to the protein level of filamin A in a normal control sample, wherein the anti-cancer therapy is selected from the group consisting of (a) radiation therapy, (b) chemotherapy, (c) surgery for resecting tumor tissues, (d) hormone therapy, (e) antibody therapy, (f) immunotherapy, (g) cytokine therapy, (h) growth factor therapy, and (i) any combination of (a)-(h).

A method of treating prostate cancer in a subject suspected of having prostate cancer, comprising:

• (i) obtaining a serum sample or a plasma sample from the subject for use in identifying diagnostic information as to the protein level of filamin A, wherein the subject has elevated PSA and is symptomatic of prostate cancer, (ii) determining the protein level of filamin A in the sample from the subject, (iii) administering a therapeutically effective amount of an anti-cancer therapy to the subject if the protein level of filamin A is increased relative to the protein level of filamin A in a normal control sample, wherein the anti-cancer therapy is selected from the group consisting of (a) radiation therapy, (b) chemotherapy, (c) surgery for resecting tumor tissues, (d) hormone therapy, (e) antibody therapy, (f) immunotherapy, (g) cytokine therapy, (h) growth factor therapy, and (i) any combination of (a)-(h).